Retia Medical Wins People's Choice Award

East Lansing, Michigan (November 16, 2012): Retia Medical, LLC, announced today that it has won the People’s Choice Award in the Accelerate Michigan business plan competition.  The People’s Choice Award was based on popular voting of the over 200 people, including venture capitalists, entrepreneurs, and state and community leaders, who attended the final round.  The award includes a $10,000 prize and free legal and business services.  Retia was one of only ten finalists out of the 329 companies spanning all industries who entered the competition.  A panel of venture capitalists selected the finalists.  They evaluated the written business plan, a 10-minute presentation and a subsequent questions and answer session.  The final round consisted of a 5-minute presentation.


Two More Patents Issue

East Lansing, Michigan (November 14, 2012): Retia Medical, LLC, announced today that two of its patent applications have issued.  These patents, US 8,282,569 and US 8,273,031, expand Retia’s broad coverage in the area of cardiovascular signal processing to enable accurate monitoring of critically ill patients using less invasive sensors.

Retia Medical Poster at the Annual Meeting of the Society of Critical Care Anesthesiologists

Washington, D.C. (October 12, 2012): Retia Medical, LLC presented a poster at the Annual Meeting of the Society of Critical Care Anesthesiologists. The poster is entitled, "Improved Cardiac Output Monitoring by Innovative Pulse Contour Analysis during Common Modes of Hemodynamic Instability." It describes recent results from clinical testing showing the dramatic accuracy advantages of Retia's algorithm during the administration of common ICU drugs and major blood loss. Click here to access the poster.

Retia Medical Wins SBIR Award from NIH

East Lansing, Michigan (August 17, 2012): Retia Medical, LLC, announced today that it has received a $151,000 Small Business Innovative Research (SBIR) Phase I award from the National Institute of Health. The funding represents an initial investment from the NIH to demonstrate the clinical performance of Retia’s breakthrough less-invasive technology to monitor cardiac output. Cardiac output monitoring is very useful in early detection of circulatory shock and for optimizing therapy to improve outcomes. Standard methods such as pulmonary artery catheter are invasive and can lead to complications, resulting in reduced usage. Successful development and demonstration of this blood flow monitor can provide crucial clinical data for improved treatment of critically ill patients.

Retia Medical Raises $7 Million To Develop Accurate, Less-Invasive Cardiovascular Monitor

East Lansing, MI - August 16, 2012 – Retia Medical, a medical device company pioneering the field of cardiovascular signal processing for patient monitoring, announced it had raised $7 Million in Series A funding. The Pritzker/Vlock family office led the investment in Retia, which was co-founded by Rama Mukkamala, Associate Professor of Electrical and Computer Engineering at Michigan State University (MSU), and Marc Zemel, Chief Executive Officer, experienced entrepreneur and formerly of Becton Dickinson. Read the full release here.